Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook

Novo Nordisk A/S

04/11/2026 06:39

Overview
Denmark-based diabetes and obesity drugmaker's Q3 adjusted sales rose 4% at CER
Q3 adjusted operating profit grew 27% at CER, aided by prior-year transformation costs
Reported operating profit fell 9% at CER due to non-cash impairment charges

Outlook
Novo Nordisk now sees 2026 adjusted sales growth at -2% to +2% at CER
Company expects 2026 adjusted operating profit growth of -2% to +2% at CER
Company says improved outlook reflects higher expectations for GLP-1 product sales

Result Drivers
GLP-1 VOLUME GROWTH - Co said Q3 sales growth was driven by continued GLP-1 volume growth, especially in obesity, across US and international markets
WEGOVY PILL LAUNCHES - Uptake of Wegovy pill in the US and new international launches contributed to sales growth
OZEMPIC PILL LAUNCH - US launch of Ozempic pill saw strong early momentum, with new prescriptions doubling compared to pre-launch levels

Company press release: ID:nGNE6gL7d6

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted Revenue
 
DKK 79.20 bln
 
Q3 Adjusted EBIT
 
DKK 31.72 bln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 19 "hold" and 6 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Novo Nordisk A/S is DKK296.00, about 9.6% above its November 3 closing price of DKK270.15
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Nov 3 - Germany's Bayer Q3 sales rise on growth in pharmaceuticals division, lifts outlook
Nov 3 - Israel's Teva Q3 revenue falls 2% as generics decline
Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)